Healthcare entity
All 1 tracked stories fall under one category: regulation. David Pope is most often covered alongside BPC-157, which appears in 1 of these 1 story. The average consequence score is 6, matching the 6 beat baseline for this window. Each story carries 2 original sources on average, compared with 2.2 for the broader beat in this window.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: regulation. David Pope is most often covered alongside BPC-157, which appears in 1 of these 1 story. The average consequence score is 6, matching the 6 beat baseline for this window. Each story carries 2 original sources on average, compared with 2.2 for the broader beat in this window. David Pope appears in 1 tracked Healthcare story from July 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering David Pope. Shared-story counts are live from our verified record — not editorial picks.
A narrow FDA advisory panel vote to ease peptide compounding restrictions could trigger a rapid expansion of telehealth-delivered wellness treatments, despite a stark lack of safety data. With HHS Secretary RFK Jr. supporting access, healthcare providers must prepare for a new era of direct-to-consumer peptide therapies.
David Pope is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
